FMC-220 is a first-in-class covalent activator of p53 Y220C designed ... achieving pronounced tumor regression at low doses. This innovative drug candidate leverages a covalent design to deliver ...

This innovative drug candidate ... clinical data for FMC-376, our novel dual KRAS G12C inhibitor, and move our second development candidate, FMC-220, a first-in-class covalent p53 Y220C activator ...

FMC-220 is a first-in-class covalent activator of p53 Y220C designed to address potency and tolerability ... achieving pronounced tumor regression at low doses. This innovative drug candidate ...